Dextropropoxyfén

Dextropropoxyphene was withdrawn from the US and European markets in 2010 due to serious cardiac toxicity, including QT prolongation and fatal arrhythmias at therapeutic doses. The drug causes seizures and potentially fatal cardiac complications that cannot be reversed by naloxone. It has a narrow therapeutic index and high toxicity relative to dose. The metabolite norpropoxyphene accumulates with repeated use and contributes to cardiotoxicity. Contraindicated in individuals with suicidal ideation, substance abuse history, or cardiac conditions.

Also known as: Darvon, Capadex, Darvocet, Di-gesic, Co-proxamol

Classification

Chemical: Medicine
Chemical: Opioid
Psychoactive: Depressant
Tag: Habit-Forming
Tag: Phenylpropylamine
Tag: Synthetic opioid
Tag: Withdrawn-substance

Effects

Pain Relief
Physical Euphoria
Sedation
Respiratory Depression
Itchiness
Pupil Constriction
Cognitive Euphoria
Anxiety Suppression
Dizziness
Confusion
Dream Potentiation
Compulsive Redosing
Decreased Libido
Appetite Suppression
Dulled Perception
Orgasm Suppression
Blurred Vision
Disinhibition

Routes of Administration

Oral

Dosage

Threshold: 15 mg
Light: 30-65 mg
Common: 65-100 mg
Strong: 100-200 mg
Heavy: 200 mg

Duration

Onset: 0.3-0.5 h
Comeup: 0.5-1 h
Peak: 1-4 h
Offset: 2-4 h
After Effects: 1-6 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu